The abuse of stimulant drugs is increasing in the western United States. Although numerous case reports and animal studies suggest a link with stroke, epidemiologic studies have yielded conflicting results.
Arch Gen
E VIDENCE HAS BEEN ACCUMUlating for 2 decades supporting a link between abuse of stimulant drugs and strokes in young people. [1] [2] [3] [4] [5] [6] [7] [8] Human imaging and postmortem examination, as well as laboratory animal models, suggest that stimulant drugs, such as cocaine and amphetamines, might produce strokes by direct effects on the cerebral circulation, including elevated blood pressure, vasculitis, and cerebral vasospasm. 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The support for a link between stimulant abuse and strokes in humans has come primarily from case reports and case series of strokes in young people who have abused these drugs. Such reports led the Food and Drug Administration to issue a public health advisory on the stimulant phenylpropanolamine and a request for companies to remove it from all products 19 and to ban ephedra from over-thecounter products in February 2004. 20 The ban was struck down in April 2005 21 and then reinstated by the Tenth Circuit US Court of Appeals in August 2006. 22 Despite the many case reports, the causal link has remained controversial because of the possibility of coincidental co-occurrence from the high prevalence of drug abuse and methodologic weaknesses and conflicting findings of the 5 epidemiologic casecontrol studies and 1 cross-sectional study that have examined the association. [23] [24] [25] [26] [27] [28] Concerns over medical complications from cocaine abuse have recently been amplified by police and news reports of a rapid increase in abuse of methamphetamine, illegally produced in backyard drug laboratories from pseudoephedrine and illegally imported from Mexico. To address the problem longitudinally in a large population-representative sample that would address many of the shortcomings of prior studies, we analyzed a database of all patients hospitalized from January 1, 2000, to December 31, 2003 , in Texas hospitals covered by a state quality-of-care reporting law. Because the system generates publicly reported quality indicators, THCIC electronically edits records submitted by hospitals for consistency and conformity to its data collection procedures. Records failing the edits are returned to the hospital for correction, and then resubmitted. The THCIC then builds the database that each submitting hospital reviews, corrects, and certifies. The THCIC database contains the following 11 diagnosis fields: 1 admitting diagnosis, 1 principle discharge diagnosis, 8 secondary discharge diagnoses, and 1 external cause of injury field. The completeness of documentation of comorbidities for mortality adjustment in state discharge data from record systems providing 9 diagnosis fields (sensitivity, 0.926) has been shown to be virtually the same as that from record systems providing 25 discharge fields (sensitivity, 0.933). 31 In the THCIC database, all 9 diagnosis fields were used in 13. 
METHODS

STATEWIDE HOSPITAL DATABASE
CASE DEFINITION OF ACUTE STROKE
Acute strokes were defined using the ICD-9-CM codes in the Agency for Healthcare Research and Quality's Inpatient Quality Indicator 17 ( Table 1) . 32 To define strokes, we searched in only the principal discharge diagnosis field, which has been shown to maximize the sensitivity and specificity of stroke ascertainment. 33 There were 1887 all-type strokes in Strokes were further categorized as hemorrhagic, ischemic, or "other" only in the 2003 data, the only year in which the distinction was accurately coded by the hospitals. Before a coding rule change by the Centers for Medicare and Medicaid Services in October 2002, hospitals were not required to make the distinction. 34 In 2003, 937 hemorrhagic and 998 ischemic strokes occurred. Analyses of secular trends during the 4 years were performed for all-type strokes combined.
DEFINITIONS OF RISK FACTORS
We defined all conditions that might predispose to stroke (Table 1) 23 from the codes in all available diagnosis fields to maximize the completeness of ascertainment. We defined abuse of a given drug by the ICD-9-CM codes for either abuse or dependence. To capture those most likely to have a close temporal relationship between stroke and substance abuse, patients with diagnoses coded as "in remission" were not categorized as substance abusers for our analysis. Nonspecific codes of drug abuse or dependence not indicating the specific drug (codes 304.8, 304.9, and 305.9) were not used.
To avoid statistical disclosure for subjects with sensitive diagnoses, the THCIC database provides age in 5 broad categories (eg, 18-44 years) and does not release sex. Other coded measures used in the analysis included in-hospital death and the patients' metropolitan statistical area, defined by the US Census Bureau 35 and used as a measure of urbanity. The cause of in-hospital death was not available. Patients' race was categorized as Asian, black, white, Hispanic, or "other" (comprising patients with missing race data or those classified as American Indians, Eskimos, Aleutians, or other race); the other category accounted for 6.1% of patients.
STATISTICAL ANALYSES
The annual prevalence rates of abuse of specific drugs were defined as the number of discharges with the recorded drug abuse per 100 discharges (with the standard error of a proportion). The percentage change in drug abuse prevalence was the prevalence rate in the given year minus the prevalence rate in the baseline year 2000, divided by the prevalence rate in 2000 (with the standard error of a percentage change 36 ). The incidence rate of acute stroke was the number of discharges with codes meeting the Agency for Healthcare Research and Quality'sInpatient Quality Indicator definition for stroke per 100 000 discharges (with the standard error of a proportion). The significance of the change in rates during the 4 years was tested with the Cochrane-Armitage test for trend, which tests the null hypothesis that during the 4 years the slope of the prevalence was 0 (not changing over time). The adjusted odds ratios (ORs) for the association of risk factors with acute hemorrhagic or ischemic stroke and their 95% confidence intervals (CIs) were obtained by multivariate logistic regression. The multivariate population-attributable risk percentage was calculated from the adjusted ORs and the risk factor prevalences by the method of Bruzzi et al. 37 Statistical analyses were performed with SAS statistical software, version 9.1, for Windows (SAS Institute Inc, Cary, NC).
RESULTS
In patients hospitalized in Texas hospitals, cocaine was reported to be the second most frequently abused drug, after alcohol, and amphetamines were the fifth most frequent ( Figure 1A ). While the rates of abuse of alcohol and hallucinogens did not increase during the 4 years, the rates of abuse of cocaine, cannabis, opioids, and amphetamines increased significantly ( Figure 1A ). Of these increases, the rate of increase was greatest for amphetamines ( Figure 1B ). The prevalence of amphetamine abuse in 2003 was higher in hospitals in rural (nonmetropolitan statistical area) counties than in suburban or urban counties (OR, 1.40; 95% CI, 1.26-1.55; PϽ.001); the prevalence of cocaine abuse was lower in rural coun-ties than in urban or suburban counties (OR, 0.72; 95% CI, 0.67-0.76; PϽ.001).
The incidence rate of stroke among amphetamine abusers, cannabis abusers, and hospitalized patients without any associated abuse of alcohol, cocaine, cannabis, amphetamines, opioids, or hallucinogens trended upward from 2000 to 2003 ( Figure 1C ). The rate of increase was greatest in stroke associated with amphetamine abuse ( Figure 1D ).
Multivariate logistic regression models from 2003 identified different patterns of association with hemorrhagic and ischemic stroke ( Table 2) . Amphetamine abuse was strongly associated with hemorrhagic stroke, but not with ischemic stroke. The strength of its association with hemorrhagic stroke was more than twice that of cocaine or tobacco use, but less than that of cerebrovascular anomalies, intracranial tumors, and hypertension. Combinations of abused drugs did not significantly contribute to the logistic regression models. Alcohol abuse has been associated with hemorrhagic stroke in prior studies, 38 and trended toward significance in this model. Atrial fibrillation or flutter was a strong risk factor for ischemic stroke in univariate analysis (OR, 1.72; 95% CI, 1.04-2.85) (eTable; available at http://www.archgenpsychiatry .com), but it did not remain significant in the multivariate model because of strong collinearity with the "miscellaneous cardiac" variable (malignant neoplasm of the heart, acquired mural thrombus following myocardial infarction, heart valve disorder, prosthetic heart valve, and atrial septal defect).
After controlling for amphetamine and cocaine abuse, a summary indicator of "any illicit drug use" was not independently associated with hemorrhagic stroke (OR, 1.42; 95% CI, 0.93-2.18). The associations between amphetamine abuse and hemorrhagic stroke (P=.14 by the Breslow-Day test for homogeneity) and cocaine abuse and hemorrhagic (P=.55) or ischemic (P=.37) stroke did not vary by race.
Among persons aged 18 to 44 years in 2003, inhospital death occurred in 3763 admissions (0.46%). An analysis of in-hospital death in the 2003 data showed that hemorrhagic stroke carried a much higher risk of death than that in all other hospitalized patients (OR, 58.3; 95% CI, 49.6-68.5; PϽ.001); in contrast, the increased mortality risk from ischemic stroke was much less (OR, 11.7; 95% CI, 8.8-15.6; PϽ.001). In patients with hemorrhagic strokes, only amphetamine abuse, coagulation defects, and hypertension were strong independent predictors of in-hospital death; in contrast, in patients with ischemic stroke, only acute myocardial infarction was significantly associated with death ( Table 3) . Repeating the analysis in patients with all types of strokes combined showed that the increased risk of death from amphetamine abuse (OR, 3.92; 95% CI, 1.79-8.59; PϽ.001) was greater than the increased risk from coagulation defects (OR, 3.06; 95% CI, 1.89-4.95; PϽ.001), and 3 times higher than that from hypertension (OR, 1.29; 95% CI, 0.97-1.73; P=.08).
If the associations are causal and unbiased, in 2003 in Texas, 14.4% of hemorrhagic strokes and 14.4% of ischemic strokes in hospitals were accounted for by abuse of drugs, including amphetamines, cocaine, cannabis, and tobacco (Figure 2) . *Codes indicating "in remission" were not used. †For opioids, we also included codes 304.70 to 304.72 (combinations of opioid-type drug with any other). Nonspecific codes of substance abuse or dependence not indicating the specific substance (codes 304.8, 304.9, and 305.9) were not used.
‡Arteriovenous malformation of the brain, congenital cerebral arteriovenous aneurysm, and congenital anomalies of cerebral vessels.
§Includes hemophilia A, B, and C; congenital deficiency of other clotting factors; von Willebrand disease; disorders due to intrinsic circulating anticoagulants; defibrination syndromes; acquired coagulation factor deficiency (eg, liver disease); thrombotic thrombocytopenic purpura; and primary, secondary, and unspecified thrombocytopenia.
Benign and malignant neoplasms of the brain and meninges and hemangioma or lymphangioma of intracranial structures.
¶Malignant neoplasm of the heart, acquired mural thrombus following myocardial infarction, heart valve disorders, prosthetic heart valves, and an atrial septal defect. 
COMMENT
Controlling for other risk factors, we found that amphetamine abuse was associated with twice the risk of hemorrhagic stroke as cocaine abuse. In contrast, amphetamine abuse was not associated with increased risk of ischemic stroke, while cocaine abuse was associated with an increased risk. Amphetamine abuse, but not cocaine abuse, was associated with increased risk of death after a hemorrhagic stroke. The public health implications of these findings are heightened by growing news accounts suggesting a recent increase in methamphetamine abuse, particularly in the southwestern, western, and midwestern states. 39, 40 This concern was supported by our finding that, among hospitalized patients in Texas from 2000 to 2003, the rate of amphetamine abuse was increasing faster than that of any other drug, including cocaine, and the rate of strokes among amphetamine abusers was increasing faster than the rate of strokes among abusers of any other drug.
Animal studies support the biological plausibility of a causal link between cocaine and amphetamine abuse and strokes. Intravenous methamphetamine, in rhesus monkeys, causes microhemorrhaging, thrombosis, infarction, poor vascular filling, and fragmentation of small arterioles and capillary beds. 12, 13 Methamphetamine also has been shown to exacerbate ischemic brain injury in mice. 41 Cocaine causes vasoconstriction 11 and disruption of cerebrovascular autoregulation in the presence of increased blood pressure. 42 Past controlled epidemiologic studies in humans, beset by the difficulties of studying the medical effects of drug abuse, have not convincingly supported the link between stimulant use and stroke. Of the 4 studies providing affirmative evidence, all used the case-control design. Kaku and Lowenstein 23 linked drug abuse in general to stroke, but did not separate out stimulants from nonstimulants. Petitti et al, 24 using rigorous means to document exposure and outcome measures in a managed care population of women, found a strong association between stimulant use and stroke, but had relatively few strokes and did not separately quantify the effects of cocaine and amphetamines on hemorrhagic and ischemic stroke. Kernan et al 27 found no overall association between phenylpropanolamine-a stimulant in many overthe-counter products-and hemorrhagic stroke, but in subgroup analysis found a strong association in women but not in men. Reanalysis of the same case-control series by Morgenstern et al 28 found no overall association of ephedra-containing products with stroke, but subgroup analysis found a nonsignificant trend toward association in the group using the highest daily dose. These 2 studies 21, 43 proved controversial. Two studies by Qureshi et al 25, 26 reported the lack of association between crack cocaine use and stroke. A case-control study, 25 which excluded approximately half of the stroke cases for lack of clear drug abuse history, found paradoxical protective effects for known stroke risk factors, including smoking, alcohol abuse, and diabetes mellitus. An analysis of the Third National Health and Nutrition Examination Survey found no association between cocaine use and selfreported history of nonfatal stroke. 26 To our knowledge, no study has assessed the link between amphetamine abuse and stroke in the context of the recent increase in methamphetamine abuse in the southwestern, western, and midwestern states.
Our finding of an increasing secular trend in the prevalence rate of amphetamine abuse and the incidence rate of amphetamine-associated strokes in a hospital patient population can be explained by either an increase in amphetamine abusers in the community or an increasing intensity of use leading to more complications. National prevalence surveys of drug abuse show that the rate of methamphetamine abusers is highest in the western, southwestern, and midwestern states, 40 but apparently did not increase during the early years of this decade. 44 This suggests that the increased rate in our hospital population is because of the increased intensity of methamphetamine *The following risk factors were included in these models, but were significant in neither model: hallucinogens, acute leukemia, connective tissue disorders, human immunodeficiency virus, and acute myocardial infarction. Alcohol was not significant in either model, but we report it because it has been associated with stroke in prior studies.
†Data are given as adjusted odds ratio (95% confidence interval). *The following risk factors were included in these models, but were significant in neither model: cocaine, alcohol, opioids, cannabis, tobacco, anomalies of the cerebrovascular system, meningitis, endocarditis, atrial fibrillation or flutter, dissection, migraine, miscellaneous cardiac factors, diabetes mellitus, obesity, atherosclerosis, human immunodeficiency virus, connective tissue disorders, intracranial tumor, and acute leukemia. Hallucinogen abuse was not observed in either hemorrhagic or ischemic stroke and, therefore, was not included in the models.
†Data are given as adjusted odds ratio (95% confidence interval). use. This interpretation is supported by 2 recent reports. First, among methamphetamine abusers, the percentage meeting abuse or dependence criteria of illicit drugs during the past 12 months has increased precipitously (from 27.5% in 2002 to 59.3% in 2004) . 45 Second, the American Association of Poison Control Centers Toxic Exposure Surveillance System 46 reported a statistically significant increase in total methamphetamine-related deaths (from 13 to 23) from 2002 to 2003; deaths from cocaine abuse were virtually unchanged (from 52 to 53), and heroin-related deaths decreased (from 40 to 23).
Although case reports [47] [48] [49] [50] have suggested a link between cannabis use and stroke, to our knowledge, this is the first controlled epidemiologic study to report a significantly increased OR for this link. Human immunodeficiency virus infection was associated with ischemic stroke in univariate analysis, but did not remain significant after controlling for the other known causes. This is consistent with prior studies [51] [52] [53] [54] of human immunodeficiency virus and stroke.
A strength of our study is that it was done in a database representative of hospitalized conditions in all but the smallest rural hospitals in Texas. Because approximately 80% of patients who experience strokes are hospitalized, 24, 55 and approximately 80% of deaths within 30 days after hospital admission take place before discharge, 56 our study represents the state's stroke population reasonably well. Our findings confirmed the popular view that methamphetamine abuse is more common in rural populations, whereas cocaine abuse is more common in urban populations. The large size of the THCIC database provides unusually ample statistical power to test associations with hemorrhagic and ischemic strokes. The THCIC database, although subject to misclassification of measurements, has several characteristics that are likely to have maximized the accuracy of the data. Specifically, these include state-mandated public reporting overseen by a state agency, a standardized coding protocol, electronic auditing, and rigorous edit criteria required by law, and the fact that the number of discharge diagnoses collected did not limit the sensitivity of condition reporting. 31 Whereas the exact temporal link between last drug abuse and stroke was not quantified in the database, by not counting diagnoses of substance abuse in remission, we narrowed the measure of drug abuse to active drug users. Because case reports 8, 57, 58 have documented strokes delayed by several days to months after last use, our measures of active drug abuse should be sufficient for demonstrating epidemiologic links. In some cases, a secondary diagnosis may be the consequence of stroke rather than a risk factor. For example, while atrial fibrillation is a known risk factor for ischemic stroke, 59 it also can be a rare complication of ischemic stroke. 60 In this study, we were unable to distinguish primary from secondary or recurrent strokes; consequently, the incidence rates and population-attributable risk percentages refer to all strokes.
Still, the major concern is misclassification of variables in a database of ICD-9-CM-coded discharge diagnoses. The occurrence of acute strokes has been shown to be accurately captured by ICD-9-CM principal discharge diagnosis in 2 validation studies. 33, 61 The specificity of drug abuse histories is thought to be high when it is recorded. In a multihospital study, 62 when measured against urine toxicology test results, the sensitivity of self-report of cocaine use was 72%. A similar study 63 in an obstetrical unit found self-report sensitivities of 58% to 70% for different drugs of abuse. One third of trauma patients in the US National Trauma Data Bank received a urine toxicology screen. 64 The sensitivity of major comorbid conditions in hospital ICD-9-CM codes is generally greater than 65%. 65 The prevalence rates of amphetamine and cocaine abuse in our study were similar to those measured in the National Survey of Drug Abuse, 66 the California study 67 of women in labor, and the study by Petitti et al. 24 Misclassification of drug abuse history is an unavoidable hazard of studies of drug abuse. More to the point, however, is whether and how much such misclassification biases estimates of its associations with stroke and similar outcomes to which it predisposes. Latkin et al 68 found, in a study of human immunodeficiency virus, that failure of subjects to disclose drug abuse was strongly related to a measured scale of social desirability concerns, but the level of social desirability concerns was not associated with the rate of human immunodeficiency virus infection, thus indicating a nondifferential information bias. Magder et al 69 directly examined whether incomplete reporting of cocaine abuse biased logistic regression analyses of the association of cocaine abuse and stroke. Both studies concluded that the point estimates of the ORs are not seriously affected, while their CIs are broadened. If misclassification of drug abuse history behaves similarly in Texas hospitals, the ORs of our logistic regression models should be relatively unaffected by misclassification of drug abuse histories, and the broadening of their CIs is offset by the large sample sizes available for analysis. Finding strong associations of stroke with certain drugs of abuse, such as amphetamines, cocaine, and tobacco, but not with others, including opioids and hallucinogens, adds further confidence to the associations. Role of the Sponsor: The funding body had no role in data extraction and analyses, in the writing of the manuscript, or in the decision to submit the manuscript for publication. Additional Information: The online-only eTable is available at http://www.archgenpsychiatry.com.
